Research Analysts Set Expectations for SPTX FY2026 Earnings

Seaport Therapeutics, Inc. (NASDAQ:SPTX) – Equities research analysts at HC Wainwright decreased their FY2026 earnings estimates for Seaport Therapeutics in a research report issued on Tuesday, August 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($4.09) per share for the year, down from their prior forecast of ($3.25). HC Wainwright currently has a “Buy” rating and a $50.00 target price on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ Q1 2027 earnings at ($0.62) EPS, Q3 2027 earnings at ($0.67) EPS and FY2027 earnings at ($2.62) EPS.

Seaport Therapeutics (NASDAQ:SPTX) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($1.07).

A number of other brokerages also recently weighed in on SPTX. Wolfe Research began coverage on Seaport Therapeutics in a report on Tuesday, July 7th. They issued a “hold” rating on the stock. Leerink Partners assumed coverage on Seaport Therapeutics in a report on Tuesday, May 26th. They set an “outperform” rating and a $35.00 price target on the stock. UBS Group downgraded Seaport Therapeutics to a “sell” rating in a research report on Tuesday, June 9th. Stifel Nicolaus started coverage on shares of Seaport Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Seaport Research Partners set a $50.00 price target on Seaport Therapeutics in a research report on Wednesday, July 15th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $38.40.

Seaport Therapeutics Stock Performance

Shares of Seaport Therapeutics stock opened at $22.34 on Thursday. Seaport Therapeutics has a 1 year low of $14.85 and a 1 year high of $23.00. The stock has a market cap of $1.20 billion and a P/E ratio of -2.16. The business has a 50-day simple moving average of $19.52.

Insider Buying and Selling at Seaport Therapeutics

In related news, Director Robert J. Hombach bought 13,000 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the completion of the purchase, the director owned 13,000 shares of the company’s stock, valued at $235,820. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Seaport Therapeutics, Inc is a healthcare company in the Pharmaceuticals industry.